These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 20337484)

  • 1. Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases.
    Namboodiri HV; Bukhtiyarova M; Ramcharan J; Karpusas M; Lee Y; Springman EB
    Biochemistry; 2010 May; 49(17):3611-8. PubMed ID: 20337484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796.
    Dietrich J; Hulme C; Hurley LH
    Bioorg Med Chem; 2010 Aug; 18(15):5738-48. PubMed ID: 20621496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with p38α MAP kinase.
    Yang Y; Shen Y; Liu H; Yao X
    J Chem Inf Model; 2011 Dec; 51(12):3235-46. PubMed ID: 22097958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Explaining why Gleevec is a specific and potent inhibitor of Abl kinase.
    Lin YL; Meng Y; Jiang W; Roux B
    Proc Natl Acad Sci U S A; 2013 Jan; 110(5):1664-9. PubMed ID: 23319661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Affinity purification of protein kinases that adopt a specific inactive conformation.
    Ranjitkar P; Maly DJ
    Methods Mol Biol; 2012; 928():143-51. PubMed ID: 22956139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human p38α mitogen-activated protein kinase in the Asp168-Phe169-Gly170-in (DFG-in) state can bind allosteric inhibitor Doramapimod.
    Suplatov D; Kopylov K; Sharapova Y; Švedas V
    J Biomol Struct Dyn; 2019 May; 37(8):2049-2060. PubMed ID: 29749295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations.
    Seeliger MA; Ranjitkar P; Kasap C; Shan Y; Shaw DE; Shah NP; Kuriyan J; Maly DJ
    Cancer Res; 2009 Mar; 69(6):2384-92. PubMed ID: 19276351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steered molecular dynamics simulations reveal the likelier dissociation pathway of imatinib from its targeting kinases c-Kit and Abl.
    Yang LJ; Zou J; Xie HZ; Li LL; Wei YQ; Yang SY
    PLoS One; 2009 Dec; 4(12):e8470. PubMed ID: 20041122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BIRB-796 is not an effective ABL(T315I) inhibitor.
    O'Hare T; Druker BJ
    Nat Biotechnol; 2005 Oct; 23(10):1209-10; author reply 1210-1. PubMed ID: 16211050
    [No Abstract]   [Full Text] [Related]  

  • 10. Conformation-selective inhibitors reveal differences in the activation and phosphate-binding loops of the tyrosine kinases Abl and Src.
    Hari SB; Perera BG; Ranjitkar P; Seeliger MA; Maly DJ
    ACS Chem Biol; 2013 Dec; 8(12):2734-43. PubMed ID: 24106839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.
    Azam M; Nardi V; Shakespeare WC; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Sliz P; Veach DR; Bornmann WG; Clarkson B; Dalgarno DC; Sawyer TK; Daley GQ
    Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9244-9. PubMed ID: 16754879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational study of Gleevec and G6G reveals molecular determinants of kinase inhibitor selectivity.
    Lin YL; Meng Y; Huang L; Roux B
    J Am Chem Soc; 2014 Oct; 136(42):14753-62. PubMed ID: 25243930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis for the autoinhibition of c-Abl tyrosine kinase.
    Nagar B; Hantschel O; Young MA; Scheffzek K; Veach D; Bornmann W; Clarkson B; Superti-Furga G; Kuriyan J
    Cell; 2003 Mar; 112(6):859-71. PubMed ID: 12654251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The crystal structure of BRAF in complex with an organoruthenium inhibitor reveals a mechanism for inhibition of an active form of BRAF kinase.
    Xie P; Streu C; Qin J; Bregman H; Pagano N; Meggers E; Marmorstein R
    Biochemistry; 2009 Jun; 48(23):5187-98. PubMed ID: 19371126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational analysis of the binding specificity of Gleevec to Abl, c-Kit, Lck, and c-Src tyrosine kinases.
    Lin YL; Roux B
    J Am Chem Soc; 2013 Oct; 135(39):14741-53. PubMed ID: 24001034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular dynamics simulations show that conformational selection governs the binding preferences of imatinib for several tyrosine kinases.
    Aleksandrov A; Simonson T
    J Biol Chem; 2010 Apr; 285(18):13807-15. PubMed ID: 20200154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors.
    Canning P; Tan L; Chu K; Lee SW; Gray NS; Bullock AN
    J Mol Biol; 2014 Jun; 426(13):2457-70. PubMed ID: 24768818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzyme fragment complementation binding assay for p38alpha mitogen-activated protein kinase to study the binding kinetics of enzyme inhibitors.
    Zaman GJ; van der Lee MM; Kok JJ; Nelissen RL; Loomans EE
    Assay Drug Dev Technol; 2006 Aug; 4(4):411-20. PubMed ID: 16945014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of interactions and pharmacophore development for DFG-out inhibitors to RET tyrosine kinase.
    Gao C; Grøtli M; Eriksson LA
    J Mol Model; 2015 Jul; 21(7):167. PubMed ID: 26044359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes.
    Angell RM; Angell TD; Bamborough P; Bamford MJ; Chung CW; Cockerill SG; Flack SS; Jones KL; Laine DI; Longstaff T; Ludbrook S; Pearson R; Smith KJ; Smee PA; Somers DO; Walker AL
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4433-7. PubMed ID: 18602262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.